High-Grade Glioma Pipeline Research 2024: Comprehensive Insights About 150+ Companies and 150+ Drugs [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
This "High-grade Glioma - Pipeline Insight, 2024," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in High-grade Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. High-grade Glioma Emerging Drugs Chapters This segment of the High-grade Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. High-grade Glioma Emerging Drugs OT101: Mateon TherapeuticsOT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- PTC Therapeutics to Participate at Upcoming Investor ConferencesPR Newswire
- PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $30.00 price target on the stock, up previously from $28.00.MarketBeat
- Industry Analysts Just Made A Captivating Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
PTCT
Earnings
- 4/25/24 - Beat
PTCT
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/25/24 - Form 10-Q
- PTCT's page on the SEC website